IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms

Over the last 2 decades, omalizumab is the only anti-IgE antibody that has been approved for asthma and chronic spontaneous urticaria (CSU). Ligelizumab, a higher-affinity anti-IgE mAb and the only rival viable candidate in late-stage clinical trials, showed anti-CSU efficacy superior to that of oma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Be-Sheng, Li, Chao-Hung, Chen, Jiun-Bo, Shiung, Yu-Yu, Chu, Chia-Yu, Lee, Chih-Hung, Liu, Yaw-Jen, Kuo, Je-Hung, Hsu, Cindy, Su, Hsiao-Wen, Li, Ywan-Feng, Lai, Annie, Ho, Yueh-Feng, Cheng, Yi-Ning, Huang, Hong-Xuan, Lung, Meng-Chung, Wu, Ming-Syue, Yang, Fu-Hung, Lin, Chen-Han, Tseng, William, Yang, Jasper, Lin, Chia-Yin, Tsai, Pei-Hua, Chang, Heng-Kwei, Wang, Yi-Jen, Chen, Techeng, Lynn, Shugene, Liao, Mei-June, Wang, Chang Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337824/
https://www.ncbi.nlm.nih.gov/pubmed/35912861
http://dx.doi.org/10.1172/JCI157765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337824/
https://www.ncbi.nlm.nih.gov/pubmed/35912861
http://dx.doi.org/10.1172/JCI157765

Ejemplares similares